Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cash from Investing Activities for 3 consecutive years, with $300000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities changed N/A to $300000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$20000.0, a 97.14% increase, with the full-year FY2024 number at -$699000.0, down 66.83% from a year prior.
  • Cash from Investing Activities was $300000.0 for Q3 2025 at Mereo BioPharma, up from -$320000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $300000.0 in Q3 2025 to a low of -$700000.0 in Q1 2024.
  • A 3-year average of -$227600.0 and a median of -$320000.0 in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 67.06% in 2024, then surged 54.29% in 2025.
  • Mereo BioPharma's Cash from Investing Activities stood at -$419000.0 in 2023, then soared by 100.24% to $1000.0 in 2024, then soared by 29900.0% to $300000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Cash from Investing Activities are $300000.0 (Q3 2025), -$320000.0 (Q1 2025), and $1000.0 (Q2 2024).